

**IPAR**



**Publicly Available Assessment Report for a  
Veterinary Medicinal Product**

---

Marbodex Aural Ear Drops, Suspension for Dogs

**PRODUCT SUMMARY**

<b>EU Procedure number</b>	IE/V/0602/001 (formerly UK/V/0493/001)
<b>Name, strength and pharmaceutical form</b>	Marbodex Aural Ear Drops, Suspension for Dogs
<b>Active substances(s)</b>	Marbofloxacin, Clotrimazole, Dexamethasone
<b>Applicant</b>	Norbrook Laboratories (Ireland) Limited Rossmore Industrial Estate Monaghan Ireland
<b>Legal basis of application</b>	Generic application (Article 13(1) of Directive No 2001/82/EC)
<b>Date of Authorisation</b>	21 August 2015 (IE) 17 June 2015 (UK)
<b>Target species</b>	Dogs
<b>Indication for use</b>	Treatment of otitis externa of both bacterial and fungal origin respectively due to bacteria sensitive to marbofloxacin, and fungi especially <i>Malassezia pachydermatis</i> sensitive to clotrimazole. The product should be used based on susceptibility testing of isolated bacteria.
<b>ATCvet code</b>	QS02CA06
<b>Concerned Member States</b>	Austria, Czech Republic, Hungary, Portugal

**PUBLIC ASSESSMENT REPORT**

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

**I. SCIENTIFIC OVERVIEW**

This was a generic application made in accordance with Article 13 (1) of Directive 2001/82/EC as amended. Marbodex Aural Ear Drops, Suspension for Dogs has been developed as a generic of Aurizon Ear Drop Suspension. The reference product has been authorised in the UK since July 2001.

The product is a suspension containing 10.0 mg/ml clotrimazole, 3.0 mg/ml marbofloxacin and 0.9 mg/ml dexamethasone and is indicated for the treatment of otitis externa of both bacterial and fungal origin respectively due to bacteria sensitive to marbofloxacin, and fungi especially *Malassezia pachydermatis* sensitive to clotrimazole.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released onto the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC. The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

**II. QUALITY ASPECTS**

**II.A. Composition**

The product contains 3.0 mg/ml marbofloxacin, 10.0 mg/ml clotrimazole and 0.9 mg /ml dexamethasone (equivalent to 1.0 mg/ml dexamethasone acetate) as the active substances. The excipients are propyl gallate (E310), sorbitan oleate, silica colloidal hydrophobic and triglycerides, medium-chain.

The container/closure system consists of low-density polyethylene bottles (LDPE) and LDPE dropper inserts, sealed with an HDPE cap in volumes of 10, 20 and 30 ml. Each bottle will be provided with two PVC cannulae. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the absence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

**II.B. Description of the Manufacturing Method**

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The product is manufactured using conventional manufacturing techniques. Process validation for full-scale batches will be performed post-authorisation.

**II.C. Control of Starting Materials**

The active substances are marbofloxacin, clotrimazole and dexamethasone, established active substances described in the European Pharmacopoeia (Ph. Eur.), with appropriate data provided in Ph. Eur. Certificates of Suitability and Active Substance Master Files (ASMF). The active substances are manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The excipients are commonly used in veterinary medicines and are manufactured in accordance with the relevant Ph. Eur. monographs.

**II.C.4. Substances of Biological Origin**

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

**II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process**

Not applicable.

**II.E. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. The tests include those for identification and assay of the active substances, viscosity and microbial quality.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

**II.F. Stability**

Stability data on the active substances have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substances when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

Data were provided for batches stored at 30°C/65% RH for 9 months and 40°C/75% RH for 6 months. In-use data were supplied when broached for two and three months stored at 30°C/65% RH. The data support a shelf-life of 2 years and an in-use shelf-life of 3 months.

**G. Other Information**

- Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
- Shelf life after first opening the immediate packaging: 3 months.
- Do not store above 30°C.

### III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

#### **III.A Safety Documentation**

##### **Pharmacological Studies**

As this is a generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product has been demonstrated, the results of pharmacological studies are not required.

##### **Toxicological Studies**

As this is a generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product has been demonstrated, the results of toxicological studies are not required.

##### **User Safety**

A user risk assessment was provided in compliance with the relevant guideline which shows that the main routes of indirect exposure are dermal, ocular or oral contact. The risk to the user is low due to the minimal quantities involved. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

- Wash hands carefully after applying the product.
- Avoid contact with eyes. In the event of accidental eye contact, rinse with clean water.
- People with known hypersensitivity to fluoro(quinolones) and other compounds in the product should avoid contact with the veterinary medicinal product.

##### **Environmental Safety**

The applicant provided a Phase I environmental risk assessment in accordance with the relevant guidelines which showed that no further assessment was required. As the product is to be used in a non-food species on an individual basis it is not expected to pose a risk for the environment when used as recommended in the SPC.

### IV. CLINICAL ASSESSMENT

As this is a generic application submitted according to Article 13 (1), and bioequivalence with the reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

#### **IV.I. Pre-Clinical Studies**

As this is a generic application submitted according to Article 13 (1), and bioequivalence with the reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

##### **Resistance**

The applicant supplied data on the mechanisms of resistance to the active substances and relevant warnings are included on the SPC and product literature.

#### **IV.II. Clinical Documentation**

As this is a generic application submitted according to Article 13 (1), and bioequivalence with the reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

### V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile of the product(s) is favourable